Reviewed by Michael Gill, B. Sc.
4 Latuda Clinical Trials Near Me
Top Cities for Latuda Clinical Trials
Image of Houston in Texas.
2Active Trials
Research Site, HoustonTop Active Site
Image of Austin in Texas.
2Active Trials
Roots Behavioral HealthTop Active Site
Latuda Clinical Trials by Phase of Trial
Phase 2 Latuda Clinical Trials
1Active Latuda Clinical Trials
1Number of Unique Treatments
12Number of Active Locations
Most Recent Latuda Clinical Trials
Clinical Trial
Began Recruiting Date

What Are Latuda Clinical Trials?

Latuda (lurasidone hydrochloride) is a chemical compound in the class of atypical antipsychotics. It is used to treat bipolar 1 depression and schizophrenia.

Developed in 2003, clinical trials were conducted to test its effectiveness in the treatment of patients with schizophrenia. Trials also tested for the effects on cognitive function and mental clarity.

Latuda was approved by the FDA in 2010 to treat schizophrenia. In 2013, it was approved to treat bipolar 1 depression.

Why Is Latuda Being Studied In Clinical Trials?

Schizophrenia and bipolar are serious psychiatric illnesses that can be extremely debilitating for those who live with them. Latuda was studied to test its effectiveness and safety in treating these disorders in conjunction with other medications and long term therapy.

The main objectives of the clinical trials were two fold. The first was to measure the impact of functioning on patients taking Latuda. The second was to measure the reduction of depressive symptoms.

Latuda was found to work by blocking the receptors for the neurotransmitters serotonin, doramine, and noradrenaline. These neurotransmitters have a negative effect on individuals with schizophrenia and bipolar. By blocking the receptors, latuda helps regulate brain activity, thereby reducing symptoms. It was found that Latuda will generally begin working within 6 weeks of its first dose.

How Does Latuda Treatment Work?

Upon being diagnosed with bipolar depression or schizophrenia, a physician may prescribe the appropriate dosage of latuda along with a mood stabilizer like lithium or valproate. It is recommended that, in addition to prescription drug therapy, patients take part in therapy with a physiatrist to obtain the maximum outcome.

In clinical studies, it was found that people who added latuda to their mood stabilizer demonstrated a 36% improvement in overall functioning. Patients should be monitored regularly by a physician to measure how the prescribed dosage is working.

Some side effects may include restlessness, nausea, and drowsiness when first taking Latuda.

What Are Some Breakthrough Clinical Trials Involving Latuda?

2010: One of the first clinical trials found that Latuda may exert antidepressant effects on the brain by increasing the dopamine level in the pre-frontal cortex.

2016: In one of the first trials conducted on adolescents who'd been diagnosed with schizophrenia. Latuda was found to significantly improve the functioning of adolescents, 13 to 17 years of age. Patients were administered between 40 - 80 mg a day for 6 weeks.

2019: A clinical study was conducted to see if Latuda could be linked to liver damage. Findings reported that no significant link could be made between Latuda and liver injury.

Who Are The Key Opinion Leaders On Latuda?

• Dr. Anthony Loebel, M.D. has conducted several clinical trials involving the effects and safety of Latuda. Head of research at Sunovion, it's his job to ensure Latuda is safe and to know how it affects different groups.

• Dr. Herbert Y. Meltzer, M.D. has studied the effectiveness of Latuda in treating schizophrenia. He has conducted double blind studies, as well as placebo-based trials to test the benefits of Latuda.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.